Physician profile
Rahul Sonone
NPI 1881815801
$24,810.57
in general payments reported to CMS, 2019-2025
69 companies · $3,687 in 2025
The $3,687 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,421 · 2020: $2,363 · 2021: $6,952 · 2022: $3,247 · 2023: $3,502 · 2024: $2,638 · 2025: $3,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,711 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,710.78 |
| Education | $116.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,126.94 | 2020-2025 | Qulipta, Botox, Duopa |
| Novartis Pharmaceuticals Corporation | $1,756.90 | 2019-2025 | |
| Ucb, INC. | $1,188.18 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Allergan, INC. | $1,161.22 | 2019-2021 | |
| Emd Serono, INC. | $1,112.19 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $1,016.83 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $843.14 | 2019-2025 | Uplizna, Aimovig |
| Acadia Pharmaceuticals INC | $822.93 | 2019-2025 | Nuplazid |
| Celgene Corporation | $786.97 | 2021-2025 | Zeposia |
| Pfizer INC. | $784.02 | 2023-2025 | |
| Biogen, INC. | $772.04 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Argenx US, INC. | $764.52 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $760.30 | 2019-2024 | Ultomiris, Soliris |
| Sk Life Science, INC. | $702.89 | 2020-2025 | Xcopri |
| Sunovion Pharmaceuticals INC. | $626.79 | 2019-2022 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Sonone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.